EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 717 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 EMA Recommends Extension of Indications for Cemiplimab May 27, 2021 Germline Pathogenic Variants in CDH1, BRCA2, CHEK2, ATM, and PALB2 Associated... October 27, 2021 Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer January 24, 2022 Load more HOT NEWS Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December Living with a stoma: Neil and Lindsay share their experiences after... 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer
